Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Sep 25, 2026
TickeronGET DAILY SIGNALS
Inspire Medical Systems (INSP) Stock Climbs +11% Over 30 Days Amid Broader Recovery

Inspire Medical Systems (INSP) Stock Climbs +11% Over 30 Days Amid Broader Recovery

Key Takeaways

  • Inspire Medical Systems (INSP) shares climbed roughly 11% over the trailing 30 days, moving from about $61.80 to near $68.66.
  • The advance extends a broader recovery, with the stock up more than 50% over the trailing three months after a difficult first half of the year.
  • Investor confidence has been supported by a second-quarter earnings beat, raised 2026 guidance, and the new Project Horizon growth initiative.
  • Analyst upgrades and proposed 2027 CMS reimbursement increases for the Inspire V procedure reinforced the positive tone.
  • Coding and reimbursement disruptions, along with emerging competition, remain the primary risks to monitor.

Company Overview: Inspire Medical Systems and Its Market Position

Inspire Medical Systems (INSP) develops and commercializes minimally invasive neurostimulation treatments for moderate to severe obstructive sleep apnea. Its Inspire therapy represents the first FDA-approved hypoglossal nerve stimulation technology for patients who cannot tolerate or do not benefit from CPAP therapy. The current Inspire V system incorporates a respiratory sensor into the neurostimulator, which simplifies the implant procedure. The company sells directly to hospitals and ambulatory surgery centers in the United States, select European markets, and Japan, and has treated more than 140,000 patients since inception. It maintains a first-mover position in this segment, though competition is growing from companies such as LivaNova (LIVN) and Nyxoah (NYXH).

INSP Stock Performance: Recent 30-Day Move Compared to the Quarter

Over the trailing 30 days, INSP advanced approximately 11%, rising from a closing level near $61.80 to about $68.66. The stock touched an intraday high near $78.80 in mid-September before some profit-taking led to consolidation. This gain forms part of a larger recovery. Over the trailing three months, INSP has climbed more than 50% from roughly $43 in late June, reversing much of the earlier decline after the company lowered its 2026 outlook.

Factors Supporting the 30-Day Advance in INSP Shares

The recent 30-day gain largely reflects sustained positive sentiment after the second-quarter results reported in early August. Inspire delivered a beat-and-raise quarter, with revenue of $200.6 million and adjusted earnings of $0.14 per share both exceeding consensus estimates, and it raised full-year 2026 guidance for revenue, adjusted operating margin, and adjusted earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Analyst actions added to the momentum, including an upgrade to Outperform from Oppenheimer with an $85 price target and price-target increases from RBC, Baird, and Piper Sandler. Investors responded as well to CMS proposed 2027 reimbursement increases for the Inspire V procedure, including a 12% rise for hospital outpatient settings and a 15% increase for ambulatory surgery centers.

Drivers Behind the Three-Month Recovery Trend

The three-month uptrend reflects a broader shift in sentiment. Earlier in 2026, coding and reimbursement disruptions related to the phase-out of a key CPT code and the WISeR program slowed U.S. procedure activity and led the company to cut its 2026 outlook, which weighed on the stock. The narrative began to turn in June with the presentation of full Inspire V trial results and cardiovascular-outcome data at the American Academy of Sleep Medicine conference. The inflection point came in early August when second-quarter results beat expectations, management raised guidance, and the company launched Project Horizon, a restructuring plan expected to create about $30 million in annualized growth investment capacity. The stock rose roughly 18% in a single session after the report and continued climbing through September.

Key Items to Monitor for INSP Going Forward

Investors should track several factors in the months ahead. Third-quarter results will test whether the company can deliver the sequential improvement management has guided toward, with third-quarter revenue expected to decline 8% to 10% year over year. Final 2027 CMS reimbursement rates, expected in November, will clarify whether the proposed facility-rate increases are confirmed. The company’s revised application for a new Category 1 CPT code, targeting implementation on January 1, 2028, remains a key long-term catalyst. Execution of Project Horizon, including restructuring charges, and the pace of prior-authorization improvement will also be closely watched. Finally, competition from LivaNova’s (LIVN) recently approved aura6000 system and Nyxoah’s (NYXH) Genio platform could influence market-share dynamics. From what I see, these elements will shape the trajectory in the near term.

AI Tools in My Research Process

I often turn to Tickeron’s AI Trading Bots when evaluating systematic approaches to stocks like this one. The platform offers a range of strategies across different timeframes and performance metrics, allowing users to explore data-driven options that align with their own analysis. In this case, reviewing the bots helped confirm broader market patterns without replacing fundamental review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: INSP

INSP in downward trend: 10-day moving average broke below 50-day moving average on November 05, 2026

The 10-day moving average for INSP crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSP as a result. In 72 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for INSP turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

INSP moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for INSP entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

INSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.240) is normal, around the industry mean (4.142). P/E Ratio (13.939) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.375) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. INSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of implantable neurostimulation systems to treat obstructive sleep apnea

Industry MedicalNursingServices

Industry
Medical Specialties
Address
5500 Wayzata Boulevard
Phone
+1 844 672-4357
Employees
1333
Web
https://www.inspiresleep.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.